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Abstract
Introduction It is unclear to which level mean arterial blood
pressure (MAP) should be increased during septic shock in
order to improve outcome. In this study we investigated the
association between MAP values of 70 mmHg or higher,
vasopressor load, 28-day mortality and disease-related events in
septic shock.
Methods This is a post hoc analysis of data of the control group
of a multicenter trial and includes 290 septic shock patients in
whom a mean MAP ≥ 70 mmHg could be maintained during
shock. Demographic and clinical data, MAP, vasopressor
requirements during the shock period, disease-related events
and 28-day mortality were documented. Logistic regression
models adjusted for the geographic region of the study center,
age, presence of chronic arterial hypertension, simplified acute
physiology score (SAPS) II and the mean vasopressor load
during the shock period was calculated to investigate the
association between MAP or MAP quartiles ≥ 70 mmHg and
mortality or the frequency and occurrence of disease-related
events.
Results There was no association between MAP or MAP
quartiles and mortality or the occurrence of disease-related
events. These associations were not influenced by age or pre-
existent arterial hypertension (all P > 0.05). The mean
vasopressor load was associated with mortality (relative risk
(RR), 1.83; confidence interval (CI) 95%, 1.4-2.38; P < 0.001),
the number of disease-related events (P < 0.001) and the
occurrence of acute circulatory failure (RR, 1.64; CI 95%, 1.28-
2.11; P < 0.001), metabolic acidosis (RR, 1.79; CI 95%, 1.38-
2.32; P < 0.001), renal failure (RR, 1.49; CI 95%, 1.17-1.89; P
= 0.001) and thrombocytopenia (RR, 1.33; CI 95%, 1.06-1.68;
P = 0.01).
Conclusions MAP levels of 70 mmHg or higher do not appear
to be associated with improved survival in septic shock.
Elevating MAP >70 mmHg by augmenting vasopressor
dosages may increase mortality. Future trials are needed to
identify the lowest acceptable MAP level to ensure tissue
perfusion and avoid unnecessary high catecholamine infusions.
Introduction
Mean arterial blood pressure (MAP) is the driving force for
microvascular blood flow and thus an important determinant of
tissue perfusion [1]. In its current guidelines [2], the Surviving
Sepsis Campaign recommends to maintain a minimum MAP of
65 mmHg in patients with severe sepsis and septic shock.
Apart from physiologic knowledge [1], there is weak evidence
to support this recommendation. Although the two single-
center prospective studies specifically investigating MAP lev-
els in septic shock were small, uncontrolled and arbitrarily
chose 65 mmHg as their lowest MAP [3,4], a retrospective
cohort study supported a MAP of 65 mmHg as the critical level
for 30-day survival but was not adjusted for disease severity
[5]. The study by Rivers and colleagues targeted a MAP of 65
mmHg in severe sepsis patients but the actual MAP levels
were much higher [6]. Therefore, no clinical conclusions about
CI: confidence interval; MAP: mean arterial blood pressure; RR: relative risk; SAPS: Simplified Acute Physiology Score.Critical Care    Vol 13 No 6    Dünser et al.
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the optimum MAP level can be drawn from this study either.
Moreover, in clinical practice, individually different safety limits
are often added to the prescribed targets thus resulting in rel-
evantly higher MAP levels than originally prescribed [6-8]. Fur-
thermore, despite the latest recommendations on MAP targets
of at least 65 mmHg [2], even the most recent large clinical tri-
als of septic shock have used higher targets and resulted in
still substantially higher actual blood pressure levels during
sustained administration of catecholamines [8,9].
As vasopressor and inotropic agents are, by definition,
required to attain a certain MAP level in septic shock [10], the
MAP goal targeted crucially determines the extent of vaso-
pressor or inotropic support. Almost all recommendations of
the Surviving Sepsis Campaign regarding the use of vasopres-
sors and inotropes in septic shock are based on catecho-
lamine agents [2]. Whereas it is unquestionable that
catecholamines are highly effective drugs to counteract cardi-
ovascular instability [11], they can be associated with disease-
related events, particularly at higher dosages [12]. Numerous
side effects of catecholamines have been reported for almost
all organs and appear particularly devastating on the heart
[12]. Hence, finding the lower safe MAP levels could help to
reduce excess exposure to exogenous catecholamines and
possibly improve outcome.
This post hoc analysis of a multicenter trial investigates the
influences of MAP levels of 70 mmHg or higher and the vaso-
pressor load on 28-day mortality and disease-related events in
septic shock. Our hypothesis was that there would be no
association between 28-day mortality and MAP levels of 70
mmHg or higher. Furthermore, we hypothesized that increas-
ing vasopressor dosages may be associated with an
increased risk of disease-related events and mortality in septic
shock patients.
Materials and methods
The present study is a post hoc analysis of data of an interna-
tional, multicenter, randomized, double-blind, placebo-control-
led clinical trial that investigated the effects of the nitric oxide
inhibitor 546C88 on mortality in 797 septic shock patients
[13]. The dataset of the control group was provided to the
authors by GlaxoSmithKline, UK, the owner of the complete
original database.
The original trial was conducted from June 1997 to April 1998.
The study protocol was approved by the local ethics commit-
tee or institutional review board of each participating center.
Written informed consent was obtained from all study patients
or their next of kin.
Inclusion criteria
Patients were included in the original trial based on the follow-
ing entry criteria: 1) age of 18 years or older; 2) severe sepsis
diagnosed less than 72 hours before randomization; 3) septic
shock for less than 24 hours defined according to the defini-
tions of the American College of Chest Physicians and the
Society of Critical Care Medicine [9] associated with either a
MAP of less than 70 mmHg for 30 minutes or more (despite
fluid resuscitation) or vasopressor requirement for 30 minutes
or more to maintain a MAP of 70 mmHg or higher; 4) pulmo-
nary arterial occlusion pressure of 18 mmHg or less and 8
mmHg or higher if cardiac index less than 5 L/min/m2, and
adequate fluid resuscitation in the opinion of the investigator;
5) continuous pressure monitoring using systemic and pulmo-
nary arterial catheters; 6) commitment for full life-support
measures for the duration of the study; and 7) negative preg-
nancy test in female patients unless postpartum, previous
tubal ligation, hysterectomy, or postmenopausal. After trial
inclusion, patients were randomized to a treatment group
receiving 546C88 and a control group in which patients
received placebo.
Only data of patients allocated to the control group (n = 358)
with a mean MAP of 70 mmHg or higher (MAP targeted by the
hemodynamic study protocol) during the shock period (n =
290) were included in this post hoc analysis. Sixty-eight
patients were excluded because their average MAP during the
shock period was below the targeted level of 70 mmHg. Char-
acteristics of these patients are shown in Table S1 and S2 of
Additional data file 1.
Clinical and hemodynamic management
Throughout the study, patients were resuscitated according to
a strict hemodynamic protocol and local standards of care
[13]. Briefly, the hemodynamic protocol included a MAP target
of 70 mmHg or higher to be reached by infusion of vasopres-
sors (norepinephrine, dopamine, epinephrine, phenylephrine).
Fluid resuscitation was guided at the discretion of the attend-
ing physician and was required to attain a pulmonary capillary
occlusion pressure of 8 to 18 mmHg if cardiac index was less
than 5 L/min/m2. Inotropic therapy was instituted to maintain
cardiac index of more than 3 L/min/m2 [13].
Data for the post hoc analysis
For the present post hoc analysis the following data were
retrieved from the original trial's database: demographic data,
chronic diseases, details on the infection leading to septic
shock, need for surgery or mechanical ventilation, the Simpli-
fied Acute Physiology Score (SAPS) II [14] assessed during
24 hours after intensive care unit admission and study rand-
omization, as well as 28-day mortality. MAP values (docu-
mented at eight-hourly intervals) were averaged during the
shock period (definition see below) after randomization. Based
on these average MAP values, study patients were grouped
into quartiles. Furthermore, the type and duration of infusion,
as well as the mean dosage of catecholamine drugs during the
shock period were documented. Because different catecho-
lamine agents were used, the mean vasopressor load was cal-
culated according to a formula suggested by Russell andAvailable online http://ccforum.com/content/13/6/R181
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colleagues [9]: vasopressor load (μg/kg/min) = norepine-
phrine (μg/kg/min) + dopamine (μg/kg/min/kg/2) + epine-
phrine (μg/kg/min) + phenylephrine (μg/kg/min/10).
Finally, the original study recorded in a binary fashion the
development of the following disease-related events in all
patients during their intensive care unit stay, based on the clin-
ical assessment of the investigators: 'cardiac dysrhythmias'
(including cardiac arrest), 'acute circulatory failure', 'dissemi-
nated intravascular coagulopathy', 'acute hepatic failure', 'met-
abolic acidosis', 'acute deterioration in mental state' (not due
to sedation), 'acute renal failure', 'acute (hypoxemic) respira-
tory failure', and 'thrombocytopenia'. In addition, the total
number of disease-related events (defined as the sum of single
disease-related events) was calculated for each study patient.
Definitions
The duration of shock was defined as the time from study ran-
domization until the patient met all of the following criteria: 1)
epinephrine, norepinephrine, phenylephrine, and dobutamine
infusion of 0 μg/kg/min; 2) dopamine infusion of 3 μg/kg/min
or less; 3) dopexamine infusion of 1 μg/kg/min or less; 4) MAP
of 70 mmHg or more [13]. Pre-existence of chronic arterial
hypertension was based on contemporary definitions of the
World Health Organization. As defined in the original trial [13],
disease-related events were considered as events known to
be associated with severe sepsis and/or septic shock and
considered by the investigator as not having a reasonable pos-
sibility of being caused by 546C88 or placebo therapy.
Study endpoints
The primary endpoint of this post hoc analysis was to investi-
gate the association between MAP or MAP quartiles of 70
mmHg or higher and 28-day mortality. Furthermore, we sought
to evaluate whether this association was influenced by age,
pre-existent arterial hypertension or the mean vasopressor
load. The secondary endpoint was to investigate the associa-
tion between MAP or MAP quartiles of 70 mmHg or higher and
the occurrence of disease-related events. Again the influence
of age, pre-existent arterial hypertension and the mean vaso-
pressor load on these associations was evaluated.
Statistical analysis
The SPSS software program was used for statistical analysis
(SPSS 15.0; SPSS Inc, Chicago, IL, USA). Kolmogorov-Smir-
nov tests were applied to check for normality distribution of
data which was approximately fulfilled by all variables except
the mean vasopressor load. This variable underwent ln-trans-
formation and subsequently showed normal distribution.
Descriptive statistical methods were used to present study
variables. For comparisons between survivors and non-survi-
vors, Student's t-tests and Fisher's Exact tests were applied,
as appropriate. Binary logistic regression models were used to
answer the primary and secondary study endpoints. These
models included either 28-day mortality or the occurrence of
disease-related events as the dependent variable. MAP (lin-
ear) or MAP quartiles (categorical, applying simple-first com-
parisons) were entered as covariates. In order to adjust for
disease severity and therapeutic differences between geo-
graphic regions as well as to evaluate the influence of age, pre-
existent arterial hypertension and the mean vasopressor load,
all logistic regression models included the SAPS II (excluding
the systolic arterial blood pressure count) assessed during the
first 24 hours after randomization, the geographic region of the
study center, age, presence of chronic arterial hypertension
and the mean vasopressor load during the shock period as
covariates. None of these covariates showed relevant coline-
arity between each other or MAP (all, Spearman rank correla-
tion coefficient less than 0.35). To evaluate the association
between the total number of disease-related events, MAP and
the mean vasopressor load, linear regression models with the
same covariates as the above mentioned logistic regression
model were calculated.
In an earlier sepsis population [15] and other patient groups
[16,17], heart rate was indirectly or directly correlated with
mortality, so the association between the mean heart rate dur-
ing the shock period and 28-day mortality was evaluated in this
study population using the same adjusted logistic regression
model. As the hemodynamic protocol of the original trial did
not include heart rate targets, all patients allocated to the con-
trol group (n = 358) were included into the latter model.
For all comparisons and models, a P-value less than 0.05 was
assumed to indicate statistical significance. Throughout the
manuscript data are presented as mean values ± standard
deviation, if not otherwise indicated.
Results
Tables S1 and S2 of the Additional data file 2 present demo-
graphic and clinical data of the study population. The leading
causes of death (by day 90) were multiple organ dysfunction
syndrome (n = 61; 45.9%), refractory shock (n = 23; 17.3%),
respiratory failure (n = 20; 15%), and miscellaneous (n = 29;
21.8%). Non-survivors were older, acquired infection more
often in the intensive care unit, had a higher SAPS II after ran-
domization, more disease-related events (except for mental
deterioration) and required more and higher vasopressor dos-
ages than survivors.
There was no association between MAP quartiles and 28-day
mortality. As the only covariates SAPS II and the mean vaso-
pressor load showed a significant association with mortality in
the adjusted logistic regression model [Table S3 in Additional
data file 2]. The predicted 28-day mortality by MAP and mean
vasopressor load quartiles is displayed in Figure 1. When
introducing MAP (mmHg) as a linear variable instead of MAP
quartiles into the model it was not associated with death at dayCritical Care    Vol 13 No 6    Dünser et al.
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28 (Wald, 0.054; relative risk (RR), 0.99; 95% confidence
interval (CI), 0.95 to 1.04; P = 0.82).
MAP or MAP quartiles were not associated with the total
number of disease-related events (linear regression model;
MAP: standardized Beta-Coefficient, -0.052; P = 0.36; MAP
quartiles: standardized Beta-Coefficient, -0.035; P = 0.55) or
the occurrence of any single disease-related event. These
associations were not influenced by age or pre-existent arterial
hypertension. However, the mean vasopressor load was signif-
icantly associated with the total number of disease-related
events (standardized Beta-Coefficient, 0.225; P < 0.001). Fig-
ure 2 presents the predicted number of total disease-related
events by MAP and mean vasopressor load quartiles as pre-
dicted by the adjusted logistic regression model. The mean
vasopressor load (per ln unit) was associated with the occur-
rence of acute circulatory failure (RR, 1.64; 95% CI, 1.28 to
2.11; P < 0.001), metabolic acidosis (RR, 1.79; 95% CI, 1.38
to 2.32; P < 0.001), renal failure (RR, 1.49; 95% CI, 1.17 to
1.89; P = 0.001) and thrombocytopenia (RR, 1.33; 95% CI,
1.06 to 1.68; P = 0.01) in single adjusted logistic regression
models. Study patients still had a significantly lower mean and
maximum vasopressor load during the shock period when
compared with the 68 patients excluded from the analysis
(mean vasopressor load, 0.64 ± 1.92 vs. 2.31 ± 6.56 μg/kg/
min, P = 0.003; maximum vasopressor load, 1.19 ± 3.54 vs.
3.06 ± 7.4 μg/kg/min, P = 0.01) [Figure S1 in Additional data
file 1].
The mean heart rate during the shock period was associated
with 28-day mortality in the adjusted logistic regression model
(RR 1.029; 95% CI, 1.01 to 1.047; P < 0.001) [Table S3 in
Additional data file 1]. Mean heart rates in the highest sixtile
(>122 bpm) were associated with a significantly higher 28-
day mortality than heart rates in the lowest sixtile (<92 bpm).
Again, the mean vasopressor load revealed the strongest
association with 28-day mortality.
Discussion
The results of this post hoc analysis confirmed our study
hypothesis that MAP levels exceeding 70 mmHg were not
associated with 28-day mortality or the occurrence of disease-
related events in patients with septic shock. In contrast, any
increase of MAP over 70 mmHg achieved by an increase of
vasopressor dosages appears to be associated with the
number of disease-related events and mortality.
A limitation of our study is that analysed data were collected
more than a decade ago and it can be argued that hemody-
namic management of septic shock has changed since then.
Specifically, the recent Surviving Sepsis Campaign recom-
mended maintaining a minimum MAP of 65 mmHg as
opposed to 70 mmHg in this trial. However, the most recent
large clinical trials in septic shock patients suggest that rec-
ommendations to tolerate lower MAP levels have not become
standard in clinical practice. Indeed, in the Vasopressin in
Figure 1
28-day mortality by MAP and mean vasopressor load quartiles as pre- dicted by the adjusted logistic regression model 28-day mortality by MAP and mean vasopressor load quartiles as pre-
dicted by the adjusted logistic regression model. Mean arterial blood 
pressure (MAP) quartile I = 70 to 74.3 mmHg; MAP quartile II = 74.3 
to 77.8 mmHg; MAP quartile III = 77.8 to 82.1 mmHg; MAP quartile IV 
= 82.1 to 99.7 mmHg.
Figure 2
Number of DRE by MAP and mean vasopressor load quartiles as pre- dicted by the adjusted logistic regression model Number of DRE by MAP and mean vasopressor load quartiles as pre-
dicted by the adjusted logistic regression model. Mean arterial blood 
pressure (MAP) quartile I = 70 to 74.3 mmHg; MAP quartile II = 74.3 
to 77.8 mmHg; MAP quartile III = 77.8 to 82.1 mmHg; MAP quartile IV 
= 82.1 to 99.7 mmHg. DRE = disease-related events.Available online http://ccforum.com/content/13/6/R181
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Septic Shock and Catecholamines in Septic Shock CATS tri-
als, the mean MAP achieved during septic shock was about
75 to 80 mmHg (two standard deviations up to 110 mmHg)
[8] and about 75 (two standard deviations up to 90 to 100
mmHg) [9], respectively. Similarly, the mean norepinephrine
dose infused during the first two days after randomization was
about 1.1 μg/kg/min (two standard deviations up to 5 μg/kg/
min) in the CATS trial [8]. Infusion of even higher catecho-
lamine dosages in critically ill patients with septic shock have
lately been reported by others [18]. Furthermore, a recent clin-
ical study has suggested that targeting higher MAP by
increasing norepinephrine resulted in an increase in global
oxygen delivery and tissue oxygenation [19]. Moreover, hemo-
dynamic goals in our study patients other than MAP were com-
parable with current recommendations [2,13]. Accordingly,
the results of our analysis appear to be clinically relevant still
today.
It is important to note that all statistical models in this analysis
were adjusted for factors commonly presumed to influence the
association between MAP and mortality. An important covari-
ate was disease severity as assessed by SAPS II, which
should have unmasked gross influences of the underlying dis-
ease on the association between MAP and mortality. Nonethe-
less, it is conceivable that although SAPS II is a reliable
measure of disease severity and excellent predictor of mortal-
ity [14], it may not reflect the true extent of cardiovascular fail-
ure and other cofactors that impact on 28-day mortality.
Furthermore, despite including 290 patients into the analysis,
the sample sizes in MAP quartiles may have been too small to
uncover statistical significance. Nonetheless, given a RR ratio
of 0.99 (95% CI, 0.95 to 1.04) per mmHg MAP increase for
death at day 28, it is unlikely that significance would have been
reached had more patients been included.
This analysis included 290 of the 358 patients who were
included in the control group of the original trial. Sixty-eight
patients had to be excluded because the goal to maintain a
MAP of at least 70 mmHg during the shock period could not
be achieved. As the hemodynamic protocol of the original trial
strictly required a MAP of 70 mmHg or higher, it must be
assumed that patients who did not attain this MAP level were
either too sick to achieve the target (vasopressor-resistant
hypotension) or had undergone violations of the hemodynamic
protocol. Both options preclude meaningful comparisons
between the 68 patients excluded and the current study pop-
ulation as well as the evaluation of the association between
MAP levels less than 70 mmHg and mortality in septic shock.
Accordingly, although our results indicate that MAP levels of
70 mmHg or higher are not associated with improved outcome
in septic shock patients, they cannot prove whether a MAP of
70 mmHg is optimal for survival or if the critical MAP level is
lower than that. We therefore hypothesize that identification of
a critical MAP level lower than 70 mmHg could further
decrease vasopressor exposure, the frequency of disease-
related events and mortality in septic shock patients. This
hypothesis should be tested in future prospective studies.
The present data, which were collected from patients treated
in 124 intensive care units worldwide, are in accordance with
results of previous single-center studies. Two prospective
studies evaluating the effects of different MAP levels on tissue
perfusion and renal function in septic shock observed that
increasing MAP from 65 to 85 mmHg did not improve sys-
temic oxygen metabolism, skin microcirculatory blood flow,
splanchnic perfusion nor renal function [3,4]. Similar to our
results, relevant increases of norepinephrine were required to
increase MAP from 65 to 85 mmHg in both studies. Two ret-
rospective studies applying similar statistical models observed
that the critical MAP for 30 or 28-day mortality in septic shock
and sepsis was 65 [5] and 60 mmHg [20], respectively.
Neither age nor pre-existent arterial hypertension relevantly
influenced the association between MAP and 28-day mortality
or the occurrence of disease-related events including renal
failure. However, considering the wide CIs of the influence of
pre-existent hypertension on the association between MAP
and mortality, it is possible that the present analysis yielded
false-negative results. Based on current physiologic and
pathophysiologic understanding [1], it would be expected that
in elderly and/or chronic hypertensive patients organ autoreg-
ulation curves, particularly renal, are shifted to the right and
higher MAP levels needed to preserve organ function and
ensure survival. Preliminary results in another sepsis popula-
tion similarly suggest that neither age nor chronic arterial
hypertension has a clinically relevant impact on the association
between MAP and mortality [20].
Metabolic acidosis related to catecholamine therapy has been
typically observed during epinephrine infusion and may origi-
nate from epinephrine-related acceleration of metabolism and/
or induction of tissue hypoperfusion [21,22]. In earlier studies,
catecholamines have repeatedly been associated with dis-
ease-related events on cardiac function ranging from ischemia
to myocardial stunning and apoptosis [12]. Tachycardia is a
particularly common and well-known side effect of catecho-
lamine therapy [12]. The significant association between heart
rate during the shock period and 28-day mortality in this
patient population confirms the results of an earlier prospec-
tive observational study in 48 septic shock patients [15].
Whereas beneficial effects of vasopressors have been
reported [11] and adrenergic vasopressors are recommended
as first-line agents in septic shock [2], we observed an inde-
pendent association between the mean vasopressor load dur-
ing shock and both the development of disease-related events
as well as death at day 28. Two recent studies reporting
adverse effects of catecholamine vasopressors on organ func-
tion [23] and mortality [24] in septic shock support our results.
Furthermore, the findings of the present analysis are in line
with earlier data suggesting harmful effects of excess catecho-Critical Care    Vol 13 No 6    Dünser et al.
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lamine exposition in general critically ill patient populations. For
example, Boldt and colleagues showed that circulating plasma
levels of catecholamines were higher in non-surviving when
compared with surviving surgical intensive care unit patients
[25]. A randomized trial that investigated the outcome effects
of supranormal oxygen delivery in a diverse group of critically
ill patients reported higher in-hospital mortality in patients
receiving liberal catecholamine therapy than in control patients
exposed to standard care [26].
Important limitations must be considered when interpreting
the results of this study. First, and probably most importantly,
mean values of punctually instead of continuously recorded
MAPs were analysed. Thus, the true course of MAP may have
been under- or over-estimated. Additionally, it is possible that
some patients changed between MAP quartiles during the
shock period but were eventually grouped into one quartile
based on their average MAP. Second, as the original study
was performed in the late 1990s the definition of some dis-
ease-related events does not correspond to current recom-
mendations. This is particularly relevant for the definition of
renal failure [27] and disseminated intravascular coagulation
[28], which has recently been newly defined based on interna-
tional consensus. Furthermore, the occurrence of disease-
related events was documented during the intensive care unit
stay after study randomization. Although more than half of non-
surviving study patients did not achieve shock resolution and
developed disease-related events during the evaluated shock
period, it is possible that some disease-related events
occurred either after shock resolution or during a renewed
shock episode during which MAP and the mean vasopressor
load were not evaluated. When drawing clinical conclusions
from our results caution is warranted because the MAP quar-
tiles analysed were retrospectively defined and can not be
considered as treatment goals. Finally, it must be considered
that this post hoc analysis was performed in an uncontrolled
patient cohort, and its results must not be considered to have
the same validity as those of a randomized, controlled trial.
Conclusions
MAP levels of 70 mmHg or higher do not appear to be asso-
ciated with improved survival in septic shock. However, aug-
menting vasopressor dosages to elevate MAP to more than 70
mmHg may increase mortality. Future trials are needed to iden-
tify the lowest acceptable MAP level to ensure tissue perfusion
and avoid unnecessary high catecholamine infusions.
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